HBV reactivation after start of bulevirtide mono-treatment for a HBV/HDV coinfected patient: a case report

Zeitschrift Fur Gastroenterologie(2023)

Cited 0|Views7
No score
Abstract
Background Bulevirtide is the first in-label treatment option for HBV/HDV coinfection in combination with nucleos(t)ide (NA) analogues or as monotherapy. We report a case of a patient with hepatitis B reactivation after start of bulevirtide monotreatment, which resulted in the need for a NA-start.
More
Translated text
Key words
hbv/hdv,mono-treatment
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined